Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease

Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline

“…While a majority of US adults with ASCVD were recommended for add-on lipid-lowering therapy, a very small percentage were taking ezetimibe or PCSK9 inhibitor. Prior studies of US adults have reported a low percentage of adults with very high-risk ASCVD to be taking ezetimibe or PCSK9 inhibitor [ 3 , 4 , 14 ]. However, these prior studies were conducted in clinic-based populations and/or among adults with health insurance.…”

“…In previous studies of adults with ASCVD, those with very-high ASCVD risk according to the 2018 AHA/ACC cholesterol guideline had 2 to 3 times higher risk for recurrent ASCVD events compared to those without very-high ASCVD risk [ 2 , 3 ]. Furthermore, prior studies using administrative claims data for US Veterans and adults with commercial or government health insurance suggest that a low percentage of adults with very-high ASCVD risk are taking ezetimibe or a PCSK9 inhibitor [ 3 – 5 ]. The percentage of adults with very-high ASCVD risk recommended and taking these medications among a general US population sample is unclear.…”

Association of systemic immune-inflammation index with diabetic kidney disease in patients with type 2 diabetes: a cross-sectional study in Chinese population

“…Dyslipidaemia was defined as either incident abnormal lipid laboratory results (comprised of TC >200 mg/dL, TG >150 mg/dL, LDL-C >130 mg/dL, or HDL-C <40 mg/dL) or incident lipid-lowering medications prescriptions (consisting of prescription of statins, bile acid resins, and fibrates) ( 18 , 38 ). In accordance to the AHA/ACC 2018 cholesterol management guidelines, atherosclerotic cardiovascular disease (ASCVD) consisted of CHD (myocardial infarction, angina, or coronary revascularization), stroke (hemorrhagic and ischemic stroke), and symptomatic PAD (i.e., a history of PAD with claudication, gangrene or ulceration, peripheral artery revascularization, or major amputation secondary to PAD) ( 39 , 40 ). DR was determined by using fundus photography (Canon Inc., Kanagawa, Japan), which was performed by an ophthalmologist ( 31 ).…”

Dynamics of Blood Lipid Profile Indicators in Patients with Acute Myocardial Infarction with Concomitant Type 2 Diabetes Mellitus Depending on the Chosen Treatment Tactics

“…Muntner P. et al у своєму дослідженні проаналізували історії хвороби 20668 пацієнтів, які перенесли гострий коронарний синдром (ГКС) у вигляді ГІМ чи нестабільної стенокардії протягом минулого року (n = 3626), ГІМ у давніс-тю більше 1 року тому (n = 7572), ішемічний інсульт (n = 3551), симптоматичне захворювання периферичних артерій (n = 5919). В ході дослідження було виявлено, що з 16344 пацієнтів (94,0%) з серйозними подіями ASCVD в анамнезі відповідали визначенню рекомендацій щодо рівня холестерину AHA/ACC 2018 року для дуже високого ризику, включаючи 92,9%, 96,5%, 93,1% і 96,2% з нещодавно перенесеним ГКС, ГІМ давністю більше 1 року, ішемічним інсультом та симптоматичним захворюванням периферичних, відповідно [17].…”